NDASUBLINGUALTABLET
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
6/8 — Strong
Drug Shortage Active
NOCDURNA is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
NOCDURNA (desmopressin acetate) by Ferring Pharmaceuticals is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. Approved for nocturia. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOCDURNA is a sublingual tablet formulation of desmopressin acetate approved in 2018 for treating nocturia. It works by binding to vasopressin 2 (V2) receptors in the kidney's collecting ducts to increase water reabsorption and reduce nighttime urine production. The drug represents a novel oral route option for managing nighttime urinary frequency.
$2MPart D
Peak3.9 years to LOEProduct is at peak lifecycle with modest Part D penetration (2,686 claims, $2M spend in 2023), suggesting a mature niche market with limited commercial expansion potential and a lean commercial team.
Mechanism of Action
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Indications (1)
Clinical Trials (2)
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Started Jul 2021
1,099,551 enrolled
Adverse Drug Event
Desmopressin Acetate 0.2 mg Tablets, Fasting
Started Jul 2003
48 enrolled
Healthy
Worked on NOCDURNA at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.